Skip to main content
ALIVUS LIFE SCIENCES LIMITED logo

ALIVUS LIFE SCIENCES LIMITED — Investor Relations & Filings

Ticker · ALIVUS ISIN · INE03Q201024 LEI · 335800RYVA1DKP696G32 BSE.NS Manufacturing
Open in API
Filings indexed 352 across all filing types
Latest filing 2025-11-14 Regulatory Filings
Country IN India
Listing BSE.NS ALIVUS

About ALIVUS LIFE SCIENCES LIMITED

https://www.alivus.com

Alivus Life Sciences Limited is a pharmaceutical organization dedicated to the formulation, production, and commercialization of a broad spectrum of healthcare solutions. The company operates across multiple therapeutic categories, including gastroenterology, anti-infectives, pain management, and nutritional supplements. Its product range includes diverse delivery formats such as tablets, capsules, syrups, and injectable medications. Alivus Life Sciences focuses on maintaining rigorous quality control protocols and manufacturing excellence to deliver reliable therapeutic outcomes. The company utilizes a robust distribution infrastructure to supply its pharmaceutical products to healthcare providers and patients, prioritizing the accessibility of essential medicines and the continuous expansion of its therapeutic portfolio.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short notice addressed to stock exchanges regarding upcoming meetings with investors and analysts. It references Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) – Regulations, 2015, which pertains to disclosure of material events or information. The content is about scheduling investor/analyst meetings, not a financial report, earnings release, or detailed presentation. The document length is only 1992 characters, indicating it is a brief announcement rather than a detailed report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-11-14 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a detailed transcript of an earnings call held by Alivus Life Sciences Limited for the quarter and half year ended September 30, 2025. It includes management commentary on financial results, business performance, outlook, and a Q&A session with analysts. The text references the earnings call date, financial figures for the quarter and half year, and forward-looking statements typical of earnings call transcripts. The document is not a brief announcement, certification, or a report publication notice but a full transcript of the call. Therefore, the appropriate classification is Call Transcript (CT).
2025-11-13 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 70% confidence The document is a letter addressed to stock exchanges regarding the uploading of the audio recording of the Q2 FY2026 Earnings Call. It references SEBI regulations related to disclosure requirements and provides a link to the audio recording. The document does not contain the transcript or financial data itself, but rather confirms the availability of the earnings call recording. The document length is short (1744 characters), and it is an announcement about the earnings call audio recording, not the transcript or financial report. Therefore, it fits best under the category of Call Transcript (CT) since it relates directly to the earnings call, but since it only announces the audio recording and does not provide the transcript, the closest appropriate classification is Call Transcript (CT) with moderate confidence.
2025-11-07 English
Investor Presentation
Investor Presentation Classification · 100% confidence The document is titled 'Investor Presentation – Q2 FY 25-26' and is addressed to stock exchanges referencing regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, which mandates disclosure of material events including investor presentations. The content includes detailed financial performance data for Q2 FY26, including revenue, EBITDA, PAT, segmental performance, market mix, and company overview. The document is approximately 15,000 characters long, indicating it is a full presentation rather than a brief announcement. The presence of forward-looking statements, detailed financial metrics, and strategic commentary aligns with the characteristics of an investor presentation. Therefore, the document is best classified as an Investor Presentation (IP).
2025-11-06 English
Press Release
Earnings Release Classification · 95% confidence The document is a press release announcing the financial results for the quarter and half year ended September 30, 2025. It includes detailed financial performance metrics such as revenue, EBITDA, PAT, margins, cash flow, and operational highlights. The document is dated November 6, 2025, and references Q2FY26 and H1FY26 results, indicating it is a quarterly earnings announcement. The length of the document (6593 characters) and the presence of substantive financial data confirm it is not merely an announcement of a report but the actual earnings release. Therefore, the document fits the definition of an Earnings Release (ER). H1 2026
2025-11-06 English
Outcome of Board Meeting
Regulatory Filings
2025-11-06 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.